Teva to lose CFO, with turnaround still under construction
Two years ago, Kåre Schultz took on the gargantuan challenge of fixing a financially troubled, debt-laden Teva with a sparse pipeline. He responded by initiating a sweeping restructuring by cutting thousands of jobs, executing facility closures, trimming board compensation and overhauling the Isreal-based company’s senior executive team. One of his moves was to officially promote Michael McClellan to chief financial officer. Along with its second-quarter results on Wednesday, Teva said McClellan was departing for personal reasons.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.